Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $53.2 million.

  • Lucid Diagnostics' Liabilities and Shareholders Equity rose 13541.02% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year increase of 3391.31%. This contributed to the annual value of $30.7 million for FY2024, which is 1263.29% up from last year.
  • According to the latest figures from Q3 2025, Lucid Diagnostics' Liabilities and Shareholders Equity is $53.2 million, which was up 13541.02% from $38.7 million recorded in Q2 2025.
  • Lucid Diagnostics' Liabilities and Shareholders Equity's 5-year high stood at $62.1 million during Q1 2022, with a 5-year trough of $22.6 million in Q3 2024.
  • Its 4-year average for Liabilities and Shareholders Equity is $38.3 million, with a median of $34.1 million in 2024.
  • In the last 5 years, Lucid Diagnostics' Liabilities and Shareholders Equity plummeted by 3476.23% in 2024 and then skyrocketed by 13541.02% in 2025.
  • Lucid Diagnostics' Liabilities and Shareholders Equity (Quarter) stood at $32.5 million in 2022, then decreased by 16.12% to $27.3 million in 2023, then increased by 12.63% to $30.7 million in 2024, then surged by 73.2% to $53.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $53.2 million for Q3 2025, versus $38.7 million for Q2 2025 and $32.8 million for Q1 2025.